This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Jiangjiang Hu: Innovator in Bispecific Antibody Development
Introduction
Jiangjiang Hu is a prominent inventor based in Sichuan, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapeutic agents. His work focuses on recombinant bispecific antibodies, which have the potential to revolutionize cancer treatment.
Latest Patents
Jiangjiang Hu holds a patent for "Recombinant bispecific antibodies to PD-L1 and CTLA-4." This patent includes a recombinant bispecific antibody against CTLA-4 and PD-L1, a nucleic acid molecule for encoding the antibody, a vector, and a host cell comprising the nucleic acid molecule. Additionally, it outlines a method for preparing the antibody, as well as a pharmaceutical composition that includes the bispecific antibody and its usage in the preparation of the pharmaceutical composition. He has 1 patent to his name.
Career Highlights
Jiangjiang Hu is currently employed at Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. His role at the company allows him to apply his expertise in antibody development and contribute to cutting-edge research in the biopharmaceutical industry.
Collaborations
He collaborates with talented colleagues, including Tongtong Xue and Liang Xiao, who share his commitment to advancing biopharmaceutical innovations.
Conclusion
Jiangjiang Hu is a key figure in the development of bispecific antibodies, with a focus on improving cancer therapies. His innovative work and collaborations position him as a valuable contributor to the field of biopharmaceuticals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile